公开(公告)号：US20230212254A1

公开(公告)日：2023-07-06

申请号：US17904221

申请日：2021-02-15

申请人： BEIJING YONGTAI RUIKE BIOTECHNOLOGY COMPANY LTD ,  PHAROS VACCINE INC.

发明人： Hoeon KIM ,  Choonju JEON ,  Yu WANG ,  Namchul JUNG

IPC分类号： C07K14/725 ,  C12N5/0783 ,  C12N15/86 ,  C12N9/90 ,  A61K35/17 ,  C07K14/705 ,  C07K14/435 ,  C07K14/005 ,  C07K14/47 ,  A61P35/02

CPC分类号： C07K14/7051 ,  A61K35/17 ,  A61P35/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/4748 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70578 ,  C07K14/70596 ,  C12N5/0636 ,  C12N9/90 ,  C12N15/86 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/72 ,  C12N2740/15043 ,  C12N2740/15071

摘要： The present invention relates to an immune cell that are engineered to overexpress cell signaling pathway modulator(s) and a use thereof. As a specific example, an immune cell expressing a fusion protein comprising a chimeric antigen receptor and a cell signaling pathway modulator(s) performs an immune response by selecting a target cancer cell by a chimeric antigen receptor expressed on a cell membrane. In this case, the cell signaling pathway modulator is overexpressed in the cytoplasm, thereby being capable of regulating the activity of an immune cell. Therefore, the fusion protein comprising a chimeric antigen receptor and cell signaling pathway modulator(s), and the immune cell engineered to overexpress the cell signaling pathway modulator(s) of the present invention can be usefully used in the treatment of cancer.